定义耐治疗双极性抑郁症:ISBD工作组的建议
Eduard Vieta1,2,3,4, Roger S McIntyre5, Trisha Suppes6
1Bipolar and Depressive Disorders Unit, Hospital Clinic de Barcelona, Barcelona, Spain.
Bipolar disorders
|August 14, 2025
概括
建立了对抗治疗双极性抑郁症 (TRBD) 的共识定义,将其确定为对至少两种充足的药理疗法缺乏反应. 这种标准化的定义旨在改善双相情感障碍的临床试验和研究.
科学领域:
- 精神病学是一个精神病学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 显著一部分双相情感障碍患者经历了耐治疗双相情感抑郁症 (TRBD).
- 缺乏普遍接受的定义阻碍了TRBD的研究和治疗开发.
- 国际双极障碍学会 (ISBD) 召集了一个工作组来解决这个问题.
研究的目的:
- 建立治疗耐药双极性抑郁症 (TRBD) 的标准化定义.
- 促进TRBD临床试验和研究的一致性.
- 引导治疗策略,并为TRBD的监管途径提供信息.
主要方法:
- 进行了全面的文献审查.
- 对现有临床试验数据进行了分析.
- 专家共识会议举行,以制定定义.
主要成果:
- TRBD被定义为在至少两次经批准,适当剂量和坚持药理治疗后,未能达到显著和持续的临床反应.
- 概述了双极性I (BD-I) 和双极性II (BD-II) 抑郁症的特定批准治疗方法和持续时间.
- 对于BD-I,治疗包括奎蒂亚平,卢拉西,奥兰扎平/西,卡里普拉辛和卢马特佩龙.
- 对于BD-II,治疗包括奎蒂亚平和卢马特佩龙.
结论:
- 建立的共识定义为临床试验和研究的一致性提供了清晰度.
- 这一定义是解决TRBD未满足需求的基本步骤.
- 未来的努力将集中在完善定义以实现现实世界的临床应用,并优化患者护理.
相关概念视频
Psychosis: Goals of Pharmacotherapy
209
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
209
Antidepressant Drugs: MAOIs and Other Agents
349
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
349
Mania and Antimanic Drugs: Overview
320
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
320
Electroconvulsive Therapy
189
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
189
Bipolar Disorder
143
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
143
Drug Therapy
98
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
98


